Device Trial Radar · NCT01891760
Long-Term Follow-Up to the DEVO Pivotal Trial of Dermagraft(R) to Treat Venous Leg Ulcers
Last checked: Nov 21, 2026Latest source record: Aug 21, 2013 (this record)Source: ClinicalTrials.govMethods & limitations
Sponsor
- Lead sponsor
- Shire Regenerative Medicine, Inc.Not on our public-company list
- Sponsor type
- Industry
- First posted
- Jul 3, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
* Observe the long-term (1-year) outcomes of Dermagraft, compared with conventional treatment of four-layer compression bandaging therapy alone, in subjects who completed the ABH-Dermagraft-001-08 study. * Study Hypothesis: N/A (Long-term follow-up study)
Conditions
- Venous Leg Ulcer
Interventions
DermagraftDevice
Dermagraft treatment regimen of one application applied topically to the ulcer, weekly, for a maximum of 8 weeks (8 application maximum).
ProforeDevice
Four-layer compression bandaging therapy.
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of study ulcer recurrenceTime frame: 1 year
Locations
28 sites in 6 countries. Site status is shown where the registry gives one.
Carl T. Hayden VA Medical Center
Phoenix, Arizona
27 more study sites with a free account
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.